Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Autonomix Medical, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
Di | Autonomix Medical Announces exercise of warrants for $2.5M gross proceeds | 1 | Seeking Alpha | ||
Di | Autonomix Medical, Inc. Exercise of Warrants for $2.5 Million Gross Proceeds | 2 | GlobeNewswire (USA) | ||
Mo | Autonomix Medical: Aktie legt nach Erteilung von Patent für "Smart Torquer"-Technologie zu | - | Investing.com Deutsch | ||
Mo | Autonomix Medical stock gains after securing smart torquer patent | 1 | Investing.com | ||
Mo | Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications | 105 | GlobeNewswire (Europe) | With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar... ► Artikel lesen | |
07.07. | Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment | 1 | GlobeNewswire (USA) | ||
AUTONOMIX MEDICAL Aktie jetzt für 0€ handeln | |||||
30.06. | Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase ("PoC 2") of Proof-of-Concept Human Clinical Study | 128 | GlobeNewswire (Europe) | Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1... ► Artikel lesen | |
27.06. | Autonomix erhält US-Patent für nervensensitive Medizintechnologie | 5 | Investing.com Deutsch | ||
27.06. | Autonomix receives US patent for nerve-sensing medical technology | 1 | Investing.com | ||
27.06. | Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology | 388 | GlobeNewswire (Europe) | Patent supports the Company's broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity... ► Artikel lesen | |
05.06. | Autonomix set to expand cancer pain treatment trial | 2 | Investing.com | ||
05.06. | Autonomix erweitert klinische Studie zur Behandlung von Krebsschmerzen | - | Investing.com Deutsch | ||
05.06. | Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain | 4 | GlobeNewswire (USA) | ||
29.05. | Autonomix Medical, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
22.05. | AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech | 2 | Zacks | ||
16.05. | Autonomix picks up key nerve ablation catheter patent | 1 | MassDevice | ||
14.05. | Autonomix Medical, Inc.: Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event | 1 | GlobeNewswire (USA) | ||
13.05. | Autonomix plans expansion phase for cancer pain trial | 2 | Investing.com | ||
13.05. | Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market | 267 | GlobeNewswire (Europe) | Discussion in Virtual Investor CEO Connect focuses on Company's planned follow-on market expansion study phase ("PoC 2") of proof-of-concept trial; Access Here Additional indications potentially double... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
GENEDX | 82,95 | 0,00 % | Rackspace US, Inc.: Rackspace Technology und Sema4.ai stellen die erste skalierbare KI-Agent-Lösung für Unternehmen vor | Die unternehmensgerechte Lösung schließt die Lücke zwischen KI-Experimenten und umfassender TransformationSAN ANTONIO, June 18, 2025®) und die Anwendungsmanagement-Expertise von Rackspace mit der fortschrittlichen... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 47,680 | +2,49 % | Siemens Healthineers-Aktie: Kurs heute nahezu konstant (46,19 €) | Wenig Kursbewegung aktuell bei der Siemens Healthineers-Aktie . Zuletzt zahlten Investoren für das Papier 46,19 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Siemens... ► Artikel lesen | |
PRIVIA HEALTH GROUP | 20,300 | 0,00 % | Privia Health Group, Inc.: Privia Health Reports First Quarter 2025 Financial Results | Strong First Quarter Performance and Operating ExecutionEnters the State of ArizonaFull-Year 2025 Outlook Raised to Mid- to High End of Guidance Ranges for All Metrics with Attributed Lives Unchanged... ► Artikel lesen | |
FRESENIUS | 42,390 | +1,19 % | Aktie von Fresenius SE & Co. KGaA heute am Aktienmarkt kaum gefragt: Kurs fällt (41,21 €) | An der deutschen Börse notiert die Fresenius SE & Co. KGaA-Aktie derzeit ein wenig leichter. Die Aktie notiert zur Stunde bei 41,21 Euro. Der Anteilsschein von Fresenius+Co KgaA verzeichnet aktuell... ► Artikel lesen | |
LIFESTANCE HEALTH GROUP | 4,270 | 0,00 % | LifeStance Health (LFST) Appoints Vaughn Paunovich as Chief Technology Officer | ||
FRESENIUS MEDICAL CARE | 46,490 | +1,18 % | Fresenius Medical Care-Aktie: Dunkle Vorzeichen! | Die Fresenius Medical Care-Aktie steht am Montag unter Druck und das nicht ohne Grund. Das belastet den DAX-Konzern jetzt, und darum könnte hier ein Verkauf aktuell die beste Option sein. Unter Druck... ► Artikel lesen | |
PHETON | 23,560 | 0,00 % | Pheton Holdings Ltd - S-8, Securities to be offered to employees in employee benefit plans | ||
BRIGHTSPRING HEALTH SERVICES | 21,310 | 0,00 % | BrightSpring Health Services, Inc. Reports First Quarter 2025 Financial Results and Increases Full Year 2025 Guidance | LOUISVILLE, Ky., May 02, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
GERRESHEIMER | 48,060 | +0,29 % | Gerresheimer stoppt Übernahmegespräche - Aktie bricht ein | Das Hin und Her, was eine mögliche Übernahme des Verpackungsherstellers Gerresheimer angeht, hat nun ein Ende. Das Unternehmen hat die Gespräche mit Finanzinvestoren über ein potenzielles Angebot abgebrochen.... ► Artikel lesen | |
CASTLE BIOSCIENCES | 16,800 | 0,00 % | Castle Biosciences, Inc.: FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx-Melanoma Test | FRIENDSWOOD, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its... ► Artikel lesen | |
OUTSET MEDICAL | 19,440 | 0,00 % | Outset Medical, Inc.: Outset Medical Appoints Renee Gaeta as Chief Financial Officer | SAN JOSE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity... ► Artikel lesen | |
KESTRA MEDICAL TECHNOLOGIES | 16,720 | 0,00 % | KESTRA MEDICAL TECHNOLOGIES, LTD. - 10-K, Annual Report | ||
CARL ZEISS MEDITEC | 51,55 | +1,58 % | JPMORGAN stuft CARL ZEISS MEDITEC AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Carl Zeiss Meditec mit einem Kursziel von 41 Euro auf "Underweight" belassen. Das dritte Geschäftsquartal der Jenaer dürfte... ► Artikel lesen | |
ALIGNMENT HEALTHCARE | 12,410 | 0,00 % | Alignment Healthcare USA, LLC: High Quality, Increased Member Satisfaction, Better Access to Care and Improved Outcomes Highlight Alignment Healthcare's Impact in 2024 | ||
INCANNEX HEALTHCARE | 1,005 | 0,00 % | Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) | NEW YORK and MELBOURNE, Australia, April 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing... ► Artikel lesen |